214 related articles for article (PubMed ID: 28810622)
1. Oral N-acetylcysteine for prophylaxis of contrast-induced nephropathy in patients following coronary angioplasty: A meta-analysis.
Li JX; Jin EZ; Yu LH; Li Y; Liu NN; Dong YM; Li X; Li XQ
Exp Ther Med; 2017 Aug; 14(2):1568-1576. PubMed ID: 28810622
[TBL] [Abstract][Full Text] [Related]
2. Intravenous N-acetylcysteine for prevention of contrast-induced nephropathy: a meta-analysis of randomized, controlled trials.
Sun Z; Fu Q; Cao L; Jin W; Cheng L; Li Z
PLoS One; 2013; 8(1):e55124. PubMed ID: 23383076
[TBL] [Abstract][Full Text] [Related]
3. N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials.
Zagler A; Azadpour M; Mercado C; Hennekens CH
Am Heart J; 2006 Jan; 151(1):140-5. PubMed ID: 16368307
[TBL] [Abstract][Full Text] [Related]
4. Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy during Cardiac Catheterisation and Percutaneous Coronary Intervention (CONTRAST): A multi-centre, randomised, controlled trial.
Chong E; Poh KK; Lu Q; Zhang JJ; Tan N; Hou XM; Ong HY; Azan A; Chen SL; Chen JY; Ali RM; Fang WY; Lau TW; Tan HC
Int J Cardiol; 2015 Dec; 201():237-42. PubMed ID: 26301645
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of N-acetylcysteine plus sodium bicarbonate in the prevention of contrast-induced nephropathy after cardiac catheterization and percutaneous coronary intervention: A meta-analysis of randomized controlled trials.
Zhao SJ; Zhong ZS; Qi GX; Tian W
Int J Cardiol; 2016 Oct; 221():251-9. PubMed ID: 27404685
[TBL] [Abstract][Full Text] [Related]
6. N-acetylcysteine for the prevention of contrast-induced nephropathy in patients with pre-existing renal insufficiency or diabetes: a systematic review and meta-analysis.
Kang X; Hu DY; Li CB; Ai ZS; Peng A
Ren Fail; 2015 Nov; 37(10):297-303. PubMed ID: 26458505
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of N-Acetylcysteine for the Prevention of Contrast-Induced Nephropathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Xu R; Tao A; Bai Y; Deng Y; Chen G
J Am Heart Assoc; 2016 Sep; 5(9):. PubMed ID: 27663415
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy of pharmacological interventions for contrast-induced nephropathy prevention after coronary angiography: a network meta-analysis from randomized trials.
Ma WQ; Zhao Y; Wang Y; Han XQ; Zhu Y; Liu NF
Int Urol Nephrol; 2018 Jun; 50(6):1085-1095. PubMed ID: 29404930
[TBL] [Abstract][Full Text] [Related]
9. The effectiveness of N-Acetylcysteine in preventing contrast-induced nephropathy in patients undergoing contrast-enhanced computed tomography: a meta-analysis of randomized controlled trials.
Wu MY; Hsiang HF; Wong CS; Yao MS; Li YW; Hsiang CY; Bai CH; Hsu YH; Lin YF; Tam KW
Int Urol Nephrol; 2013 Oct; 45(5):1309-18. PubMed ID: 23283594
[TBL] [Abstract][Full Text] [Related]
10. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect.
Webb JG; Pate GE; Humphries KH; Buller CE; Shalansky S; Al Shamari A; Sutander A; Williams T; Fox RS; Levin A
Am Heart J; 2004 Sep; 148(3):422-9. PubMed ID: 15389228
[TBL] [Abstract][Full Text] [Related]
11. Intrarenal application of N-acetylcysteine for the prevention of contrast medium-induced nephropathy in primary angioplasty.
Aslanger E; Uslu B; Akdeniz C; Polat N; Cizgici Y; Oflaz H
Coron Artery Dis; 2012 Jun; 23(4):265-70. PubMed ID: 22343798
[TBL] [Abstract][Full Text] [Related]
12. Does N-acetylcysteine reduce the incidence of contrast-induced nephropathy and clinical events in patients undergoing primary angioplasty for acute myocardial infarction?
Tanaka A; Suzuki Y; Suzuki N; Hirai T; Yasuda N; Miki K; Fujita M; Tanaka T
Intern Med; 2011; 50(7):673-7. PubMed ID: 21467697
[TBL] [Abstract][Full Text] [Related]
13. Trimetazidine reduces contrast-induced nephropathy in patients with renal insufficiency undergoing coronary angiography and angioplasty: A systematic review and meta-analysis (PRISMA).
Heshmatzadeh Behzadi A; Amoozgar B; Jain S; Velasco N; Zahid U; Abbasi H; Alasadi L; Prince MR
Medicine (Baltimore); 2021 Mar; 100(10):e24603. PubMed ID: 33725824
[TBL] [Abstract][Full Text] [Related]
14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
15. N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial.
Jo SH; Koo BK; Park JS; Kang HJ; Kim YJ; Kim HL; Chae IH; Choi DJ; Sohn DW; Oh BH; Park YB; Choi YS; Kim HS
Am Heart J; 2009 Mar; 157(3):576-83. PubMed ID: 19249432
[TBL] [Abstract][Full Text] [Related]
16. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography.
Oldemeyer JB; Biddle WP; Wurdeman RL; Mooss AN; Cichowski E; Hilleman DE
Am Heart J; 2003 Dec; 146(6):E23. PubMed ID: 14661012
[TBL] [Abstract][Full Text] [Related]
17. N-acetylcysteine versus ascorbic acid or N-acetylcysteine plus ascorbic acid in preventing contrast-induced nephropathy: A meta-analysis.
Feng Y; Huang X; Li L; Chen Z
Nephrology (Carlton); 2018 Jun; 23(6):530-538. PubMed ID: 28452187
[TBL] [Abstract][Full Text] [Related]
18. A randomized trial of intravenous n-acetylcysteine to prevent contrast induced nephropathy in acute coronary syndromes.
Jaffery Z; Verma A; White CJ; Grant AG; Collins TJ; Grise MA; Jenkins JS; McMullan PW; Patel RA; Reilly JP; Thornton SN; Ramee SR
Catheter Cardiovasc Interv; 2012 May; 79(6):921-6. PubMed ID: 21542122
[TBL] [Abstract][Full Text] [Related]
19. Trimetazidine Decreases Risk of Contrast-Induced Nephropathy in Patients With Chronic Kidney Disease: A Meta-Analysis of Randomized Controlled Trials.
Nadkarni GN; Konstantinidis I; Patel A; Yacoub R; Kumbala D; Patel RA; Annapureddy N; Pakanati KC; Simoes PK; Javed F; Benjo AM
J Cardiovasc Pharmacol Ther; 2015 Nov; 20(6):539-46. PubMed ID: 25715308
[TBL] [Abstract][Full Text] [Related]
20. Acetylcysteine has No Mechanistic Effect in Patients at Risk of Contrast-Induced Nephropathy: A Failure of Academic Clinical Science.
Sandilands EA; Rees JMB; Raja K; Dhaun N; Morrison EE; Hickson K; Wraight J; Gray T; Briody L; Cameron S; Thompson AP; Johnston NR; Uren N; Goddard J; Treweeke A; Rushworth G; Webb DJ; Bateman DN; Norrie J; Megson IL; Eddleston M
Clin Pharmacol Ther; 2022 Jun; 111(6):1222-1238. PubMed ID: 35098531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
